Schizophrenia Pharmacotherapy: What Role for Perphenazine? (Video 1:39 minutes)

Key Takeaways

• Positioning perphenazine as an evidence-based maintenance alternative is reasonable for patients stable on FGAs or needing a lower-cost option, while individualizing risk–benefit versus SGAs.
• CATIE data showed similar discontinuation and symptom outcomes versus several atypicals, undermining assumptions of universal SGA superiority and highlighting adherence, comorbidity, and side-effect burden as key determinants.
• Weight gain is possible but typically less pronounced than with olanzapine or clozapine; baseline BMI and early trajectory help identify patients needing intensified lifestyle and monitoring interventions.
• Metabolic monitoring should still follow guideline standards, while recognizing perphenazine’s greater propensity for extrapyramidal symptoms and tardive dyskinesia, which may dictate dose adjustments or switching.